Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of SI-613 in enthesopathy (lateral epicondylitis and plantar fasciitis)
jRCT2080223702Phase 2Completed
- Sponsor
- Seikagaku Corporation
- Start
- Nov 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diclofenac etalhyaluronate in enthesiopathy, Lateral Epicondylitis (LET) and plantar fasciitis (3 arms), sponsored by Seikagaku Corporation. Primary endpoint: Change from baseline in pain during movement at 4 weeks. Started Nov 2017; status: completed.
02
Drugs
diclofenac etalhyaluronate
03
Conditions
enthesiopathyLateral Epicondylitis (LET)plantar fasciitis
Beyond the preview
Go deeper on jRCT2080223702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223702.